Title : Platelet-Rich Plasma (prp) as a therapeutic approach for joint osteoarthritis: A focus on regenerative potential and quality control in clinical trials
Abstract:
Osteoarthritis (OA) remains one of the most prevalent degenerative joint diseases, causing significant morbidity and reducing quality of life globally. Recent advances in regenerative medicine have identified Platelet-Rich Plasma (PRP) as a promising therapeutic option for joint regeneration in OA due to its concentration of growth factors and cytokines that promote tissue repair. However, the clinical efficacy of PRP in OA treatment has been met with variability in outcomes, largely due to inconsistencies in PRP preparation, application protocols, and patient response.
This presentation will explore the regenerative potential of PRP for joint osteoarthritis, highlighting its biological mechanisms and therapeutic impact. Based on current scientific and clinical evidence, we will focus on the role of PRP in stimulating cartilage repair, modulating inflammation, and improving joint function. As well as discussing cohort recent publication: Systematic Review of Platelet-Rich Plasma in Medical and Surgical Specialties: Quality, Evaluation, Evidence, and Enforcement
Therefore, the presentation will incorporate findings from our recent publication, which addresses the critical need for rigorous quality control in PRP clinical trials. Standardizing PRP preparation, characterization, and administration can minimise the variability in clinical outcomes, ensuring more reliable and reproducible results across studies. Our research underscores the importance of harmonizing PRP methodologies to improve the translation of preclinical successes into clinical practice.
Attendees will gain a comprehensive understanding of the current landscape of PRP in OA treatment, including its limitations, potential, and the imperative role of quality control in advancing its clinical application. This presentation aims to foster discussion on how standardized protocols can optimize PRP's therapeutic potential, moving the field toward more effective regenerative interventions for osteoarthritis.
Keywords: Platelet-Rich Plasma, Osteoarthritis, Joint Regeneration, Clinical Trials, Quality Control, Regenerative Medicine, PRP Standardization
